Comparative insight into surfactants mediated amyloidogenesis of lysozyme

International Journal of Biological Macromolecules

Volumn 83, Issue , 2016, Pages 315-325

  Chaturvedi, Sumit K ^a   Khan, Javed M ^a,b   Siddiqi, Mohammad K ^a   Alam, Parvez ^a   Khan, Rizwan H ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Amyloid fibril and aggregation; Lysozyme; PH; Surfactants

Indexed keywords

AMYLOID; CONGO RED; LYSOZYME; SURFACTANT; HEN EGG LYSOZYME; PROTEIN AGGREGATE;

AMYLOIDOGENESIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BINDING ASSAY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CHEMICAL INTERACTION; CIRCULAR DICHROISM; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EGG; FLUORESCENCE MICROSCOPY; HEN; HYDROPHOBICITY; ISOTHERMAL TITRATION CALORIMETRY; LIGHT SCATTERING; NONHUMAN; PH; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; STATIC ELECTRICITY; TRANSMISSION ELECTRON MICROSCOPY; TURBIDITY; ULTRAVIOLET RADIATION; ANIMAL; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS;

AMYLOID; ANIMALS; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MURAMIDASE; PROTEIN AGGREGATES; SURFACE-ACTIVE AGENTS;

EID: 84949677542     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2015.11.053     Document Type: Article

References (66)

1. Sgarbossa A. Natural biomolecules and protein aggregation: emerging strategies against amyloidogenesis. Int. J. Mol. Sci. 2012, 13:17121-17137.
2. Clark A.H., Kavanagh G.M., Ross-Murphy S.B. Globular protein gelation-theory and experiment. Food Hydrocoll. 2001, 15:383-400.
3. Berson J.F., Theos A.C., Harper D.C., Tenza D., Raposo G., Marks M.S. Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J. Cell Biol. 2003, 161:521-533.
4. Chapman M., Robinson L., Pinkner J., Roth R., Heuser J., Hammar M., Normark S., Hultgren S. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 2002, 295:851-855.
5. True H.L., Berlin I., Lindquist S.L. Epigenetic regulation of translation reveals hidden genetic variation to produce complex traits. Nature 2004, 431:184-187.
6. Nakayashiki T., Kurtzman C.P., Edskes H.K., Wickner R.B. Yeast prions [URE3] and [PSI+] are diseases. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10575-10580.
7. Morozova-Roche L., Malisauskas M. A false paradise - mixed blessings in the protein universe: the amyloid as a new challenge in drug development. Curr. Med. Chem. 2007, 14:1221-1230.
8. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
9. Ross C.A., Pickart C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004, 14:703-711.
10. Selkoe D.J. Folding proteins in fatal ways. Nature 2003, 426:900-904.
11. Westermark P., Wernstedt C., Wilander E., Hayden D., O' Brien T., Johnson K. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:3881-3885.
12. Stefani M., Dobson C. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 2003, 81:678-699.
13. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001, 24:1121-1159.
14. Dobson C.M. Protein folding and misfolding. Nature 2003, 426:884-890.
15. Brange J., Havelund S., Hougaard P. Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm. Res. 1992, 9:727-734.
16. Mahler H.C., Muller R., Friess W., Delille A., Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 2005, 59:407-417.
17. Kiese S., Papppenberger A., Friess W., Mahler H.C. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J. Pharm. Sci. 2008, 97:4347-4366.
18. Strambini G.B., Gonnelli M. Protein stability in ice. Biophys. J. 2007, 92:2131-2138.
19. Clark O.H., Duh Q.Y. Primary hyperparathyroidism. A surgical perspective. Endocrinol. Metab. Clin. North Am. 1989, 18:701-714.
20. Vaiana S.M., Manno M., Emanuele A., Palma-Vittorelli M.B., Palma M.U. The role of solvent in protein folding and in aggregation. J. Biol. Phys. 2001, 27:133-145.
21. Dzwolak W., Grudzielanek S., Smirnovas V., Ravindra R., Nicolini C., Jansen R., Loksztejn A., Porowski S., Winter R. Ethanol-perturbed amyloidogenic self-assembly of insulin: looking for origins of amyloid strains. Biochemistry 2005, 44:8948-8958.
22. Durbin S.D., Feher G. Protein crystallization. Annu. Rev. Phys. Chem. 1996, 47:171-204.
23. Foguel D., Suarez M.C., Ferrao-Gonzales A.D., Porto T.C., Palmieri L., Einsiedler C.M., Andrade L.R., Lashuel H.A., Lansbury P.T., Kelly J.W., Silva J.L. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9831-9836.
24. Munishkina L.A., Henriques J., Uversky V.N., Fink A.L. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. Biochemistry 2004, 43:3289-3300.
25. Uversky V.N., Fink A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 2004, 1698:131-153.
26. Khan J.M., Qadeer A., Chaturvedi S.K., Ahmad E., Rehman S.A., Gourinath S., Khan R.H. SDS can be utilized as an amyloid inducer: a case study on diverse proteins. PLoS ONE 2012, 7:e29694.
27. Zhao H., Jutila A., Nurminen T., Wickstrom S.A., Keski-Oja J., Kinnunen P.K. Binding of endostatin to phosphatidylserine-containing membranes and formation of amyloid-like fibers. Biochemistry 2005, 44:2857-2863.
28. Hasegawa K., Tsutsumi-Yasuhara S., Ookoshi T., Ohhashi Y., Kimura H., Takahashi N., Yoshida H., Miyazaki R., Goto Y., Naiki H. Growth of beta(2)-microglobulin-related amyloid fibrils by non-esterified fatty acids at a neutral pH. Biochem. J. 2008, 416:307-315.
29. Rodziewicz-Motowidlo S., Juszczyk P., Kolodziejczyk A.S., Sikorska E., Skwierawska A., Oleszczuk M., Grzonka Z. Conformational solution studies of the SDS micelle-bound 11-28 fragment of two Alzheimer's beta-amyloid variants (E22K and A21G) using CD, NMR, and MD techniques. Biopolymers 2007, 87:23-39.
30. Price W., Tsuchiya F., Arata Y. Time dependence of aggregation in crystallizing lysozyme solutions probed using. Biophys. J. 2001, 80:1585-1590.
31. Nozaki Y., Reynolds J.A., Tanford C. The interaction of a cationic detergent with bovine serum albumin and other proteins. J. Biol. Chem. 1974, 249:4452-4459.
32. Gerken T.A., Jentoft J.E., Jentoft N., Dearborn D.G. Intramolecular interactions of amino groups in 13C reductively methylated hen egg-white lysozyme. J. Biol. Chem. 1982, 257:2894-2900.
33. Ghosh S., Pandey N.K., Bhattacharya S., Roy A., Dasgupta S. Fibrillation of hen egg white lysozyme triggers reduction of copper(II). Int. J. Biol. Macromol. 2012, 51:1-6.
34. Itzhaki L.S., Evans P.A., Dobson C.M., Radford S.E. Tertiary interactions in the folding pathway of hen lysozyme: kinetic studies using fluorescent probes. Biochemistry 1994, 33:5212-5220.
35. Rothwarf D.M., Scheraga H.A. Role of non-native aromatic and hydrophobic interactions in the folding of hen egg white lysozyme. Biochemistry 1996, 35:13797-13807.
36. Bachmann A., Segel D., Kiefhaber T. Test for cooperativity in the early kinetic intermediate in lysozyme folding. Biophys. Chem. 2002, 96:141-151.
37. Booth D.R., Sunde M., Bellotti V., Robinson C.V., Hutchinson W.L., Fraser P.E., Hawkins P.N., Dobson C.M., Radford S.E., Blake C.C.F. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 1997, 385:787-793.
38. Dumoulin M., Kumita J.R., Dobson C.M. Normal and aberrant biological self-assembly: insights from studies of human lysozyme and its amyloidogenic variants. Acc. Chem. Res. 2006, 39:603-610.
39. Merlini G., Bellotti V. Lysozyme: a paradigmatic molecule for the investigation of protein structure, function and misfolding. Clin. Chim. Acta 2005, 357:168-172.
40. Frare E., Mossuto M.F., de Laureto P.P., Tolin S., Menzer L., Dumoulin M., Dobson C.M., Fontana A. Characterization of oligomeric species on the aggregation pathway of human lysozyme. J. Mol. Biol. 2009, 387:17-27.
41. Canet D., Sunde M., Last A.M., Miranker A., Spencer A., Robinson C.V., Dobson C.M. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry 1999, 38:6419-6427.
42. Morshedi D., Ebrahim-Habibi A., Moosavi-Movahedi A.A., Nemat-Gorgani M. Chemical modification of lysine residues in lysozyme may dramatically influence its amyloid fibrillation. Biochim. Biophys. Acta (BBA): Proteins Proteomics 2010, 1804:714-722.
43. Gharibyan A.L., Zamotin V., Yanamandra K., Moskaleva O.S., Margulis B.A., Kostanyan I.A., Morozova-Roche L.A. Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic/necrotic pathways. J. Mol. Biol. 2007, 365:1337-1349.
44. Malisauskas M., Ostman J., Darinskas A., Zamotin V., Liutkevicius E., Lundgren E., Morozova-Roche L.A. Does the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicity?. J. Biol. Chem. 2005, 280:6269-6275.
45. Goddard E.D., Ananthapadmanabhan K.P. Interactions of Surfactants with Polymers and Proteins 1993, 1-427. CRC Press, Boca Raton, FL.
46. Amiri R., Bordbar A.-K., Garca-Mayoral M., Khosropour A.R., Mohammadpoor-Baltork I., Menndez M., Laurents D.V. Interactions of gemini surfactants with two model proteins: NMR, CD, and fluorescence spectroscopies. J. Colloid Interface Sci. 2012, 369:245-255.
47. Kumar S., Ravi V.K., Swaminathan R. How do surfactants and DTT affect the size, dynamics, activity and growth of soluble lysozyme aggregates?. Biochem. J. 2008, 415:275-288.
48. Sabate R., Estelrich J. Stimulatory and inhibitory effects of alkyl bromide surfactants on beta-amyloid fibrillogenesis. Langmuir 2005, 21:6944-6949.
49. Wahlstrom A., Hugonin L., Peralvarez-Marin A., Jarvet J., Graslund A. Secondary structure conversions of Alzheimer's Abeta(1-40) peptide induced by membrane-mimicking detergents. FEBS J. 2008, 275:5117-5128.
50. Rangachari V., Reed D.K., Moore B.D., Rosenberry T.L. Secondary structure and interfacial aggregation of amyloid-beta(1-40) on sodium dodecyl sulfate micelles. Biochemistry 2006, 45:8639-8648.
51. Pandey N.K., Ghosh S., Dasgupta S. Effect of surfactants on preformed fibrils of human serum albumin. Int. J. Biol. Macromol. 2013, 59:39-45.
52. Khurana R., Uversky V.N., Nielsen L., Fink A.L. Is Congo red an amyloid-specific dye?. J. Biol. Chem. 2001, 276:22715-22721.
53. Chaturvedi S.K., Ahmad E., Khan J.M., Alam P., Ishtikhar M., Khan R.H. Elucidating the interaction of limonene with bovine serum albumin: a multi-technique approach. Mol. Biosyst. 2015, 11:307-316.
54. Zaidi N., Ahmad E., Rehan M., Rabbani G., Ajmal M.R., Zaidi Y., Subbarao N., Khan R.H. Biophysical insight into furosemide binding to human serum albumin: a study to unveil its impaired albumin binding in uremia. J. Phys. Chem. B 2013, 117:2595-2604.
55. Zaidi N., Ajmal M.R., Rabbani G., Ahmad E., Khan R.H. A comprehensive insight into binding of hippuric acid to human serum albumin: a study to uncover its impaired elimination through hemodialysis. PLOS ONE 2013, 8:e71422.
56. Mir M.A., Khan J.M., Khan R.H., Dar A.A., Rather G.M. Interaction of cetyltrimethylammonium bromide and its gemini homologue bis(cetyldimethylammonium)butane dibromide with xanthine oxidase. J. Phys. Chem. B 2012, 116:5711-5718.
57. Bourgault S., Solomon J.P., Reixach N., Kelly J.W. Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion. Biochemistry 2011, 50:1001-1015.
58. Ahmad A., Muzaffar M., Ingram V.M. Ca(2+), within the physiological concentrations, selectively accelerates Abeta42 fibril formation and not Abeta40 in vitro. Biochim. Biophys. Acta 2009, 1794:1537-1548.
59. Sukenik S., Politi R., Ziserman L., Danino D., Friedler A., Harries D. Crowding alone cannot account for cosolute effect on amyloid aggregation. PLoS ONE 2011, 6:e15608.
60. Khan J.M., Chaturvedi S.K., Khan R.H. Elucidating the mode of action of urea on mammalian serum albumins and protective effect of sodium dodecyl sulfate. Biochem. Biophys. Res. Commun. 2013, 441:681-688.
61. Alam P., Rabbani G., Badr G., Badr B.M., Khan R.H. The surfactant-induced conformational and activity alterations in Rhizopus niveus lipase. Cell Biochem. Biophys. 2014, 1-8.
62. Arnaudov L.N., de Vries R. Thermally induced fibrillar aggregation of hen egg white lysozyme. Biophys. J. 2005, 88:515-526.
63. Vajda T., Perczel A. Role of water in protein folding, oligomerization, amyloidosis and miniprotein. J. Pept. Sci. 2014, 20:747-759.
64. Harper J.D., Wong S.S., Lieber C.M., Lansbury P.T. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry 1999, 38:8972-8980.
65. Motamedi-Shad N., Monsellier E., Torrassa S., Relini A., Chiti F. Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway. J. Biol. Chem. 2009, 284:29921-29934.
66. Panza G., Luers L., Stohr J., Nagel-Steger L., Weiss J., Riesner D., Willbold D., Birkmann E. Molecular interactions between prions as seeds and recombinant prion proteins as substrates resemble the biological interspecies barrier in vitro. PLoS ONE 2010, 5:e14283.